An official website of the United States government
Here's how you know
Official websites use .mil
A
.mil
website belongs to an official U.S. Department of Defense organization in the United States.
Secure .mil websites use HTTPS
A
lock (
lock
)
or
https://
means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.
Skip to main content (Press Enter).
Toggle navigation
Department of Defense Office of Inspector General
Department of Defense Office of Inspector General
Search
Search ::
Search
Search ::
Search
About
Mission and Strategic Plan
Leaders
Organization
Contact Us
DoD OIG Careers
Reports
All DoD OIG Reports
Audits and Evaluations
Administrative Investigations
Lead Inspector General Reports
Oversight of U.S. Assistance to Ukraine
COVID-19
Advisories
Reports
Project Announcement Memos
Oversight Plan
Semiannual Report to the Congress
Project Announcement Memos
Testimony
Oversight Plan
Top DoD Management and Performance Challenges
Other Publications
News
DoD OIG Press Releases
DoD OIG Multimedia
DoD OIG Testimony
Oversight of U.S. Assistance to Ukraine
Criminal Investigations
Defense Criminal Investigative Service
Law Enforcement Officer Safety Act (LEOSA) Resources
Programs
Anti-Harassment Program
Civil Liberties Program
Contractor Disclosure Program
DoD Joint Inspector General Program
Equal Employment Opportunity Program
Privacy Program
Single Audit Program
Subpoena Program
Resources
FAQs
Fraud Detection Resources
Policies
Posters and Brochures
Other Resources
Federal Activities Inventory Reform (FAIR) Act Annual Submission
Whistleblower and DoD Hotline
DoD Hotline
Whistleblower Reprisal Complaints
Whistleblower Protection Coordinator
Cash Awards Program
FOIA
Home
Criminal Investigations
Keyword
Calendar Year
Calendar Year
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
Criminal Investigation
| June 10, 2011
Danish Pharmaceutical Novo Nordisk to Pay $25 Million to Resolve Allegations of Off-label Promotion of NovoSeven
Danish Pharmaceutical Novo Nordisk to Pay $25 Million to Resolve Allegations of Off-label Promotion of NovoSeven
SHARE
PRINT
Related Documents
Danish Pharmaceutical Novo Nordisk to Pay $25 Million to Resolve Allegations of Off-label Promotion of NovoSeven